Patents by Inventor Elliot B. Grossbard

Elliot B. Grossbard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating cell proliferative disorders
    Patent number: 8481521
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: July 9, 2013
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh
  • Methods of Treating Cell Proliferative Disorders
    Publication number: 20120245127
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh
  • Methods of treating cell proliferative disorders
    Patent number: 8227455
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: July 24, 2012
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh